The responsibility rests with patients to contact CANSA for assistance. Read more...

Lung Cancer

Supported by Roche

Lung cancer is the most common cancer worldwide, accounting for 2.1 million new cases and 1.8 million deaths in 2018. (1) More than two-thirds of lung cancer patients are diagnosed at a late stage, after the cancer has spread to other parts of the body. (2) Even with surgery, radiation therapy and chemotherapy, the lung cancer 5 year survival rates are amongst the lowest of all cancer sites such as colorectal, breast and prostate. (3) If lung cancer is found at an earlier stage, when it is small and before it has spread, it is more likely to successfully be treated. (4)

There is low awareness of lung cancer in South Africa. Because early diagnosis is key, it is important that people learn to recognise the signs and symptoms of this common but serious disease. It is also important that people know that, by following the science, Roche and other industry partners have entered a new era of hope in lung cancer. That is why Roche is partnering with the Cancer Association of South Africa (CANSA) to provide a platform that will offer basic lung cancer information to increase education and awareness.

It is clear that lung cancer remains a challenge for patients and medical teams. However, the dawn of cancer immunotherapy, a new treatment option, alongside existing treatments provides hope for patients and their families. It is an incredibly exciting time for lung cancer research and treatment, both in terms of diagnostics and drug development. New information is empowering us to help lung cancer patients like never before. (5)

Roche’s Commitment to Lung Cancer

At Roche we are committed to involving patients in everything we do through our vision of Doing now what patients need next. We do this by understanding the needs and challenges faced by the patients so that we can co-create solutions and services that can best address unmet needs.A significant medical need remains for therapies that extend lives and are tolerable, particularly in the previously treated advanced and metastatic non-small cell lung cancer (NSCLC) setting, which is where immunotherapies could play an important role. “At Roche, we are committed to addressing this medical need for lung cancer patients,” said Dr Nick Mangeya, Medical Director, Roche South Africa.


1. American Lung Association. Lung Cancer. Accessed October 2017

2. Ellis, PM, Vandermeer, R. J Thorac Dis, 2011 Wetp; 3(3):183-188.

3. American Lung Association. Lung Cancer. Accessed October 2017

4.  Accessed May 2021

5. Accessed May 2021

More from Roche:

 0800 22 6622 Toll Free
 072 197 9305 English and Afrikaans
 071 867 3530 Xhosa, Zulu, Sotho and Siswati

  Find Your Care Centre

About Us | Get in Touch

Sign up to receive news and updates: